Biogen Inc. has reported new Phase 1b clinical data from the study of BIIB080, a therapy targeting tau in mild Alzheimer's disease. The data showed favorable trends on multiple exploratory endpoints of cognition and activities of daily living. The results were presented at the 2023 Clinical Trials on Alzheimer's Disease meeting. Biogen is currently recruiting for the Phase 2 CELIA study, evaluating the potential for this therapy to slow the worsening of mild cognitive impairment or mild dementia due to Alzheimer's disease. BIIB shares are trading lower by 2.26% to $246.41.